A rational design strategy and validation for protease-resistant fusion-inhibitor antiviral peptides

Viruses that wrap themselves in a fatty membrane, known as enveloped viruses, must fuse their outer layer with a human cell to cause an infection. To do this, they use a molecular key called a spike protein, which undergoes a dramatic shape change to lock the virus and the cell together. Scientists have long known that they could potentially stop this process by creating a decoy: a short piece of protein that mimics a part of the virus's own key. This decoy would bind to the spike protein, jamming the mechanism and preventing the virus from entering the cell. While this strategy works well in a test tube, it has historically failed as a medicine because the human body is full of enzymes that act like molecular scissors, chopping up these protein decoys before they can do their job.

A team of researchers has now found a way to outsmart these scissors. They discovered that the very enzyme the virus uses to unlock cells is also the one destroying the decoy proteins. By studying the specific spots where this enzyme cuts, they redesigned the decoy proteins to be invisible to the scissors while keeping their ability to jam the viral lock. When tested in living cells and in mice, these new, tougher decoys remained active for much longer than the original versions, offering a promising path toward a safe, preventative treatment that could be administered before a person is exposed to the virus.

The story begins with a specific type of virus, SARS-CoV-2, which causes COVID-19. Like many other viruses, it relies on a spike protein to breach the defenses of human cells. Inside the virus, there is a region called the heptad repeat 2, or HR2, which is crucial for the fusion process. Scientists previously tried to use a short piece of this HR2 region as a drug. The idea was that this piece would float around and bind to the virus's own HR2 region, effectively tying its hands so it could not fuse with the cell. However, in the body, these short protein pieces are fragile. The researchers suspected that a specific enzyme in the human airways, called TMPRSS2, was responsible for destroying them. This enzyme is essential for the virus to enter cells, as it cuts the spike protein to activate it. The team hypothesized that this same enzyme was also cutting up the therapeutic decoy proteins, rendering them useless.

To test this, the researchers took the original decoy proteins and exposed them to the TMPRSS2 enzyme in a lab dish. Within one hour, the enzyme had completely sliced the decoys into pieces. When they tested these chopped-up fragments in a cell-fusion experiment, they found the fragments had lost all ability to stop the virus. This confirmed that the enzyme was indeed the culprit behind the decoys' failure. The next step was to find out exactly where the enzyme was cutting. Using a technique that identifies the chemical makeup of molecules, they pinpointed three specific spots on the decoy proteins where the enzyme made its cuts. These spots were rich in basic building blocks of proteins, which the enzyme specifically targets.

Armed with this knowledge, the team set out to redesign the decoys. They needed to change the three cutting spots so the enzyme would no longer recognize them, but they had to be careful not to change the shape of the decoy so much that it could no longer bind to the virus. To solve this, they used two different strategies to find the best replacements. First, they created a massive library of millions of slightly different decoy versions and tested which ones still bound tightly to the virus's target. Second, they looked at the genetic records of SARS-CoV-2 variants found in nature to see which changes had already occurred without breaking the virus. By combining these two approaches, they identified three new versions of the decoy protein that were resistant to the enzyme but still effective at binding.

The researchers then synthesized these three new proteins and tested them. They confirmed that the enzyme could no longer cut them. In cell experiments, all three new decoys successfully stopped the virus from fusing with cells, even in the presence of the enzyme. One version, which the researchers named HR2-NHN, performed the best. To understand why this specific version worked so well, the team used a powerful imaging technique called cryo-electron microscopy to take a detailed 3D picture of the decoy bound to its target. They found that while one of the changes they made removed a strong electrical attraction between the decoy and the virus, it created a new, stable connection that held them together just as tightly. This structural insight explained why the new decoy was so potent.

The true test came when the researchers moved from cell dishes to living animals. They used mice that were susceptible to a variant of SARS-CoV-2. In these experiments, they administered the original decoy and the new, tougher HR2-NHN decoy at different times before infecting the mice with the virus. When given just before infection, both versions worked well. However, when the researchers waited twelve hours before infecting the mice, the original decoy had lost most of its power. The new HR2-NHN decoy, by contrast, remained highly effective. It continued to protect the mice even when given a full day before the virus was introduced. In a separate experiment, they measured how long the decoys stayed active in the mice's lungs. The original decoy's protective effect faded with a half-life of about eight hours, while the new decoy lasted for eleven hours. This difference meant that the new decoy could prevent infection for a significantly longer window of time.

The study also looked at how these decoys performed against different strains of the virus, including the Omicron variant. While the new decoy was slightly less effective against Omicron than against the original strain, it still outperformed the old decoy. The researchers noted that the changes made to the decoy might help it enter cells more efficiently or resist other enzymes found inside the cell, which could explain this extra resilience. The work demonstrates that it is possible to create a protein-based antiviral that does not require complex chemical modifications to survive in the body. By simply changing a few letters in the protein's code to avoid the body's natural scissors, the researchers created a drug candidate that is more stable and longer-lasting.

This approach offers a new way to think about fighting viral infections. Instead of relying on expensive chemical coatings to protect a drug, scientists can now use the virus's own weaknesses and the body's natural environment to design better medicines. The success of this strategy with SARS-CoV-2 suggests it could be applied to other dangerous viruses that use similar fusion mechanisms, such as Ebola, Nipah, and HIV. The researchers envision a future where a simple nasal spray containing these redesigned proteins could be used as a preventative measure, protecting people before they are exposed to a virus or helping to stop an infection in its early stages. The findings provide a clear, practical blueprint for turning fragile protein fragments into robust, life-saving tools.